Novel immunotherapies for prostate cancer

Area of Science:

• Oncology
• Immunology
• Cancer Therapy

Background:

• The development of immunotherapies for advanced prostate cancer has stalled since sipuleucel-T's approval, with limited success beyond pembrolizumab in select cases.
• Key challenges include an immune-excluded tumor microenvironment, dose-limiting toxicities, and short-lived anti-tumor effects, hindering clinical progress.

Purpose of the Study:

• To review the current landscape of novel immunotherapeutic strategies in clinical development for advanced prostate cancer.
• To highlight emerging approaches that leverage recent advances in drug design and cellular engineering.

Main Methods:

• Review of current clinical development data for novel immunotherapies in prostate cancer.
• Focus on chimeric antigen receptor (CAR) T cells, T cell engagers, monoclonal antibodies, and cancer vaccines.

Main Results:

• Several novel immunotherapy modalities are demonstrating promising early-phase clinical data.
• Chimeric antigen receptor (CAR) T cells, T cell engagers, monoclonal antibodies, and cancer vaccines are at the forefront of development.

Conclusions:

• Despite past challenges, recent innovations have revitalized interest in immunotherapy for prostate cancer.
• Emerging immunotherapeutic approaches show potential to overcome existing hurdles and improve patient outcomes.